Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $64 Price Target
Leerink Partners Maintains PTC Therapeutics(PTCT.US) With Hold Rating, Announces Target Price $37
PTC Therapeutics: Balancing Strong FY24 Guidance Against Regulatory Uncertainties
PTC Therapeutics, Inc. (NASDAQ:PTCT) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
PTC Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
PTC Therapeutics Is Maintained at Overweight by Cantor Fitzgerald
Express News | Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $64
PTC Therapeutics Analyst Ratings
Buy Rating Affirmed for PTC Therapeutics on Strong Q2 Performance and Promising Pipeline
PTC Therapeutics: Sell Rating Due to DMD Franchise Challenges and Pipeline Uncertainties
Express News | PTC Therapeutics : Barclays Raises Target Price to $31 From $25
Analysts Conflicted on These Healthcare Names: Cytokinetics (CYTK), Doximity (DOCS) and PTC Therapeutics (PTCT)
Barclays Sticks to Their Hold Rating for PTC Therapeutics (PTCT)
Express News | PTC Therapeutics Inc : TD Cowen Raises Target Price to $33 From $30
Express News | PTC Therapeutics Inc : JP Morgan Cuts Target Price to $51 From $53
Maintained Sell Rating for PTC Therapeutics Amidst Sales Shortfall and Regulatory Hurdles
PTC Sees FY24 Revenue $700M-$750M Vs $749M Estimate
PTC Therapeutics | 10-Q: Q2 2024 Earnings Report
PTC Therapeutics: Q2 Earnings Snapshot
Express News | PTC Therapeutics Inc - Total Revenues Were $186.7 Mln for Q2 of 2024, Compared to $213.8 Mln for Q2 of 2023